Home › Calculator › SYRE Dividend Calculator 2026
SYRE Dividend Calculator 2026
No dividendHealthcareSpyre Therapeutics, Inc. · NASDAQ
Price: $90.33 · Annual div: None · Frequency: — · Payout ratio: N/A · Ex-div: —
Calculator settings
SYRE is not a dividend-focused stock
SYRE pays a very low or no dividend (Yield: 0.00%). This calculator is designed for income-producing assets. If your goal is passive income and compounding, you might want to look at these popular alternatives:
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
SYRE Dividend Yield
Spyre Therapeutics, Inc. (SYRE) does not currently pay a regular dividend in our data, so its dividend yield is 0%.
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When SYRE pays your bills
Year your monthly dividend income covers each expense (based on current settings)
About Spyre Therapeutics, Inc. (SYRE) — Dividend Analysis 2026
Spyre Therapeutics, Inc. is a biotechnology firm operating at the preclinical stage, dedicated to creating innovative treatments for individuals afflicted with inflammatory bowel disease (IBD). Among its pipeline candidates is SPY001, a human monoclonal immunoglobulin G1 antibody specifically engineered to target and bind with the a4ß7 integrin. This particular therapy is under development for addressing both ulcerative colitis and Crohn's disease, two forms of IBD. Furthermore, Spyre Therapeutics is advancing SPY002, another human monoclonal antibody that aims to interact with tumor necrosis factor-like ligand 1A (TL1A). A synergistic approach is also being explored with SPY120, a compound that merges the anti-a4ß7 action of SPY001 with the anti-TL1A activity of SPY002. All these programs are currently undergoing preclinical evaluation. Beyond these, the company's early-stage portfolio encompasses several additional promising candidates: SPY003, an anti-IL-23 monoclonal antibody; SPY004, a monoclonal antibody with a novel mechanism of action; SPY130, which combines anti-a4ß7 and anti-IL-23 antibodies; and SPY230, a dual antibody therapy featuring anti-TL1A and anti-IL-23 components. Originally incorporated in 2013, the organization was previously known as Aeglea BioTherapeutics, Inc., before rebranding to Spyre Therapeutics, Inc. in November 2023. Its headquarters are located in Waltham, Massachusetts.
SYRE Dividend & DRIP — Frequently Asked Questions
Does SYRE pay a dividend?
No. Spyre Therapeutics, Inc. (SYRE) has not paid a regular dividend in the last 12 months in our data, so its dividend yield is 0% and it produces no dividend income.
How can I get dividend income instead of SYRE?
Dividend ETFs such as SCHD, VYM or JEPI pay regular income. Open their DRIP calculators to see what $10,000 would earn per month and how reinvesting grows it.
Does SYRE have a DRIP (dividend reinvestment plan)?
A DRIP reinvests dividends into new shares. SYRE has no regular dividend in our data, so there is nothing to reinvest.
Stocks similar to SYRE
Forward dividend yield from the latest data · open any DRIP calculator
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full SYRE DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open SYRE position with:
🌍 SYRE Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold SYRE.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 0.00% | -2.80% | $0 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 0.00% | -2.80% | $0 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 0.00% | -2.80% | $0 / yr |
| 🇬🇧 UK ISA | 0% | 0.00% | -2.80% | $0 / yr |
| 🇬🇧 UK Taxable | 8.75% | 0.00% | -2.80% | $0 / yr |
| 🇨🇦 TFSA | 0% | 0.00% | -2.80% | $0 / yr |
| 🇨🇦 CA Taxable | 25% | 0.00% | -2.80% | $0 / yr |
| 🇦🇺 Super (pension) | 15% | 0.00% | -2.80% | $0 / yr |
| 🇦🇺 AU Taxable | 30% | 0.00% | -2.80% | $0 / yr |
| 🇩🇪 DE Taxable | 26.375% | 0.00% | -2.80% | $0 / yr |
| 🇫🇷 FR Taxable | 30% | 0.00% | -2.80% | $0 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 SYRE Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
No dividend data available for this ticker.
Based on current dividend of $0.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 SYRE Dividend Payment Schedule
SYRE pays quarterly — 4 times per year. Ex-div: —.
📊 SYRE vs Healthcare Benchmarks
How SYRE compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for SYRE sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ SYRE Insider Activity
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| M-Exempt | 2026-10-01 | 28,933 | $14.50 | $419.5K | ||
| M-Exempt | 2026-10-01 | 28,933 | $14.50 | $419.5K | ||
| Sale | 2026-10-01 | 400 | $89.24 | $35.7K | ||
| Sale | 2026-10-01 | 16,605 | $90.35 | $1.50M | ||
| Sale | 2026-10-01 | 7,228 | $91.35 | $660.3K | ||
| Sale | 2026-10-01 | 2,100 | $92.70 | $194.7K | ||
| Sale | 2026-10-01 | 2,600 | $93.46 | $243.0K | ||
| Sale | 2026-10-01 | 600 | $89.14 | $53.5K | ||
| Sale | 2026-10-01 | 2,683 | $90.10 | $241.7K | ||
| Sale | 2026-10-01 | 2,638 | $91.49 | $241.4K |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Analyst Price Target
Wall Street consensusAnalyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Peer Group
Similar companies in the same sectorCompare SYRE with peers: SYRE vs ABCL · SYRE vs ARDX · SYRE vs CLDX
Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the SYRE dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Spyre Therapeutics, Inc. (SYRE) is currently trading at $90.33, 18% below its 52-week high. It does not currently pay a regular dividend.
Does SYRE Pay a Dividend? Spyre Therapeutics, Inc. Dividend Status
Spyre Therapeutics, Inc. (SYRE) is a healthcare stock trading at $90.33. It does not currently pay a regular dividend in our data, so it produces no dividend income and DRIP reinvestment does not apply. Investors seeking income often look at dividend ETFs such as SCHD, VYM or JEPI instead.
- Without a dividend, returns depend entirely on the share price.
Auto-generated from live market data. For educational purposes only — not financial advice.
Latest SYRE News
LiveProjected your SYRE DRIP returns?
If DividendFlow helped you see your future dividend income clearly, other investors deserve the same clarity. Your review takes 30 seconds and makes a real difference.